Promentis Garners $2,900,000 Series B Funding Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    826 N. Plankinton Ave. Milwaukee, WI 53203
  • Company Description
    Promentis Pharmaceuticals, Inc. is a pharmaceutical company developing novel compounds for the treatment of schizophrenia and other central nervous system disorders. Promentis’ drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other diseases.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    The Series B round really gives us the bandwidth to take the science from the pre-clinical world into the clinic.
  • M&A Terms
  • Venture Investor
    Black Horse Investments
  • Venture Investor

Trending on Xconomy